Health Technology Research Center, National Institute of Advanced Industrial Science and Technology, Ikeda, Osaka, Japan.
Neurosci Lett. 2009 Nov 6;465(1):1-5. doi: 10.1016/j.neulet.2009.08.074. Epub 2009 Sep 3.
DJ-1 was initially identified as a novel oncogene and has recently been found to be a causative gene for a familial form of Parkinson's disease (PD), viz, PARK7. Cysteine residue at position 106 (Cys-106) in DJ-1 was found to be oxidized preferentially under oxidative stress. In the present study, we developed specific antibodies against Cys-106-oxidized DJ-1 using baculovirus particles displaying the surface glycoprotein gp64-fusion protein as the immunizing agent. Western blot analysis combined with two-dimensional gel electrophoresis revealed that these antibodies specifically recognized oxidized DJ-1. Furthermore, we developed a competitive enzyme-linked immunosorbent assay (ELISA) for detecting oxidized DJ-1 and measured blood levels of oxidized DJ-1 in PD patients (n=15). It was observed that the levels of oxidized DJ-1 in erythrocytes of unmedicated PD patients were markedly higher without overlap than those of medicated PD patients and healthy subjects. No significant difference was observed in DJ-1 levels between mediated and unmediated PD patient. These results suggest the oxidative modification of DJ-1 in PD patients and the potential application of the antibody for diagnosis of PD at early-stage.
DJ-1 最初被鉴定为一种新型癌基因,最近被发现是家族性帕金森病 (PD) 的致病基因,即 PARK7。DJ-1 位置 106 位的半胱氨酸残基(Cys-106)在氧化应激下优先被氧化。在本研究中,我们使用展示表面糖蛋白 gp64 融合蛋白的杆状病毒颗粒作为免疫原,针对 Cys-106 氧化的 DJ-1 开发了特异性抗体。Western blot 分析结合二维凝胶电泳显示,这些抗体特异性识别氧化的 DJ-1。此外,我们开发了一种用于检测氧化 DJ-1 的竞争性酶联免疫吸附测定 (ELISA),并测量了 PD 患者(n=15)的血液氧化 DJ-1 水平。结果发现,未经药物治疗的 PD 患者的红细胞中氧化 DJ-1 水平明显高于药物治疗的 PD 患者和健康受试者,且两者无重叠。经药物治疗和未经药物治疗的 PD 患者的 DJ-1 水平无显著差异。这些结果提示 PD 患者 DJ-1 的氧化修饰,以及该抗体在早期诊断 PD 中的潜在应用。